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Abstract
Background: Chronic pancreatitis is an inflammatory disease which is characterized by an irreversible
conversion of pancreatic parenchyma to fibrous tissue. Beside obstructive jaundice and pseudocyst
formation, about half of the patients need surgical intervention due to untreatable chronic pain during the
course of the disease. In most of the patients with chronic pancreatitis, the head of the pancreas is the
trigger of the chronic inflammatory process. Therefore, resection of pancreatic head tissue must be the
central part of any surgical intervention. However, it is unclear to which extent the surgical procedure
must be radical in order to obtain a favourable outcome for the patients.
Design: A single centre randomized controlled, superiority trial to compare two techniques of duodenum
preserving pancreatic head resection. Sample size: 65 patients will be included and randomized
intraoperatively. Eligibility criteria: All patients with chronic pancreatitis and indication for surgical
resection and signed informed consent. Cumulative primary endpoint (hierarchical model): duration of
surgical procedure, quality of life after one year, duration of intensive care unit stay, duration of hospital
stay. Reference treatment: Resection of the pancreatic head with dissection of the pancreas from the
portal vein and transsection of the gland (Beger procedure). Intervention: Partial Resection of the
pancreatic head without transsection of the organ and visualization of the portal vein (Berne procedure).
Duration: September 2003-October 2007.
Organisation/responsibility: The trial is conducted in compliance with the protocol and in accordance
with the moral, ethical, regulatory and scientific principles governing clinical research as set out in the
Declaration of Helsinki (1989) and the Good Clinical Practice guideline (GCP). The Center for Clinical
Studies of the Department of Surgery Heidelberg is responsible for planning, conducting and final analysis
of the trial.
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Medical problem
Chronic pancreatitis is an inflammatory disease, which is
characterized by progressive and irreversible destruction
of pancreatic parenchyma and transformation into
fibrous tissue. The leading symptom of chronic pancreati-
tis is chronic pain, which requires surgical intervention in
about 50% of the patients [1].
Despite of the fact that the etiopathogenesis of pain in
chronic pancreatitis is not fully understood, the concept
of a neuroimmune interaction in the head of the pancreas
is in accordance with the observation that simple drainage
procedures seldom lead to satisfactory pain relief in the
long run in patients with an enlarged pancreatic head [2-
6]. Only surgical techniques that include resection of the
inflammatory mass in the pancreatic head have shown to
be successful in the treatment of this disease [7,8].
The Beger procedure (reference treatment)
In 1972, H.G. Beger for the first time described the tech-
nique of duodenum preserving pancreatectomy in the
treatment of patients with chronic pancreatitis (Fig. 1)
[9,10]. The rationale of this intervention is the resection of
the inflammatory mass in the pancreatic head without
large loss of unaffected parenchyma and maintenance of
the duodenal passage. Different studies have shown that
this organ preserving technique is at least as effective as
the more radical Kausch-Whipple procedure (pancreatico-
duodenectomy) regarding pain control (effective pain
diminishing in >80% within 5 years), but postoperative
morbidity and the incidence of diabetes mellitus are lower
[1,11-13].
The Berne procedure (selection of intervention)
Over the years, different variations of the duodenum pre-
serving technique have been introduced. In 1985, Frey
and Smith described a modification in which a longitudi-
nal pancreatico-jejunostomy is combined with a local
resection of the pancreatic head [14,15]. This technique
combines the principle of duodenum preserving pancre-
atic head resection with the drainage of the main pancre-
atic duct. In 1998, similar to the Frey technique, Izbicki et
al. combined the duodenum preserving resection of the
pancreatic head with a V-shaped incision of the body of
the pancreas in order to also reach II° and III° pancreatic
side branches. The results obtained with this technique
are very similar to the original Beger technique. Thirty
patients were operated without mortality. After a median
follow up of 30 months, 92% of the patients were pain
free with preserved endocrine and exocrine function [16].
The main advantage of these variations of the original
Beger procedure lies in the fact that the dissection of the
pancreas from the portal vein can be avoided, which is
regarded as the most hazardous part of the intervention
[4]. Especially in case of portal vein thrombosis, the divi-
sion of the pancreatic body from the portal vein, which is
an essential step in the Beger (and also Kausch-Whipple)
procedure, can be very demanding. Bleeding from the
portal vein in this situation can be extremely difficult to
control.
To combine the advantages of the original Beger proce-
dure with the Frey technique, we developed an additional
modification which consists in a duodenum preserving
resection of the pancreatic head in analogy to the original
Beger technique, with the difference that a small shape of
pancreatic tissue remains on the anterior wall of the portal
vein in a way that the hazardous division of vein and pan-
creatic body is avoided (Fig. 2) [17].
Study design
Aim of the study
The objective of this trial is to compare two different sur-
gical techniques for the treatment of chronic pancreatitis
with regard to complication rates, length of operation,
length of intensive care treatment, length of hospital stay,
exocrine/endocrine pancreatic function and quality of
life.
Beger procedure (reference treatment)Fi u e 1
Beger procedure (reference treatment). Reconstruc-
tion after duodenum preserving pancreatic head resection 
with a Roux en-Y jejunal loop as side-to-end and side-to-side 
pancreatico-jejunostomy.Page 2 of 6
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As estimated effect size a difference of mean operating
time of one hour between the two groups and a variability
of this difference in between the expected absolute effect
(standard deviation of one hour) is defined. Groups of 22
patients each would permit the verification of the null-
hypothesis with an α-error set at 0.05 and a β-error at
0.10, yielding a power of 90%.
To evaluate the true efficacy of the Berne procedure a per
protocol analysis is necessary. For the external validity of
the study an intention to treat approach for analysis is
requested. Due to the nature of complex surgery such as a
pancreatic resection it can be expected that one third of all
randomised patients will not receive the intended proce-
dure. Therefore at least 65 patients should be randomised.
Eligibility criteria
Inclusion criteria
• Patients of any age (>18 ys)
• Expected survival time more than 24 months
• Informed consent
Exclusion criteria
• Participation in another intervention trial that would
interfere with the intervention and outcome of this study
• Severe psychiatric disorders or neurological diseases
• Lack of compliance
• Drug and/or alcohol abuse according to local standards
Ethics, study registration and consent
The final protocol was approved by the independent eth-
ics committee of the University of Heidelberg. The study
was registered at Current Clinical Trials (ISRCTN No.
50638764). Patients who are scheduled for duodenum
preserving pancreatic head resection had a pre-treatment
visit to give the informed consent. During this visit the
patient will be screened and informed about the trial. In
the course of the conversation, the study procedure, risks,
benefits and data management will be clarified in detail.
Randomisation and procedures for minimising 
bias
Minimising systematic bias
In order to achieve comparable groups for known and
unknown risk factors, randomization will be performed.
The random allocation sequence was generated by a free
available randomization software tool [18] by a trained
independent study nurse not further involved in this trial.
She also prepared the sealed and opaque envelopes for the
randomisation procedure in the operation theatre. The
sealed randomization list was stored in the investigator
file. A sufficient number of patients will be recruited
according to the sample size calculation in order to pre-
vent random error. Patients will get randomised intra-
operatively by an independent study nurse or anaesthesi-
ologist once the surgeon decides that clinical equipoise is
given, usually after the pancreas has been prepared and
mobilised (Kocher's maneuver). All interventions will be
done as described below. Patients in whom the ran-
domised procedure cannot be performed due to technical
or anatomical reasons will be analysed according the
intention to treat principle.
Minimising treatment bias
The participating surgeons are all experienced in pancre-
atic surgery. Annually more than 300 resections of the
pancreas are performed in Heidelberg. Both procedures
used in this trial are supervised by two authors (H.F.,
M.W.B.) in order to guarantee correct execution according
to the protocol (intraoperative surgical monitoring). Con-
comitant treatment will be equal for both groups includ-
ing antibiotic prophylaxis, use of sandostatin and
anaesthesia.
Minimising measurement bias
An independent study nurse will document and monitor
the procedure in the operating theatre. Blinding in this
Berne procedure (intervention)Figure 2
Berne procedure (intervention). Reconstruction after 
duodenum preserving pancreatic head resection with a Roux 
en-Y jejunal loop as side-to-side pancreatico-jejunostomy.Page 3 of 6
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tion.
Standardized patient interviews will be performed by
blinded study nurses 6, 12 and 24 months after surgery,
using EORTC QLQ-C30 questionnaire and the disease
specific module for pancreatic diseases EORTC QLQ-
PAN26 [19,20].
Study treatment
After a midline laparotomy, wide exposure of the pancreas
is obtained by opening of the gastro-colic ligament. The
duodenum and the pancreatic head are then mobilized by
an extended Kocher maneuver. If there are any doubts on
the dignity of the pancreatic head tumour, biopsies will be
taken and pathological examination will be performed.
After exhibition of the pancreas, the randomisation will
be performed using sequentially numbered, opaque,
sealed envelopes; according to the allocation, the proce-
dure will be continued.
Beger procedure (reference treatment)
The pancreas is gently lifted and subtle dissection is per-
formed between the mesenteric vein and the body of the
pancreas, taking care to avoid injury to the major retro-
pancreatic vessels and smaller side branches. After this
step, multiple stay sutures (4/0 PDS) are placed around
the parenchyma of the pancreatic head to assign resection
margins. This is important to avoid inadvertent injury to
the duodenum and assures that a lamella of pancreatic
parenchyma along the loop of the duodenum remains
and assures blood supply. The subtotal resection of the
pancreatic head starts with the transsection of the pan-
creas above the portal vein proceeding towards the pre-
papillary common bile duct. In all phases of the
intervention meticulous haemostasis is required. Recon-
struction is performed with a Roux-en-Y loop of the jeju-
num with an end-to-side pancreatico-jejunal anastomosis
and another side-to-side anastomosis of the jejunal loop
with the remaining hollowed pancreatic head.
Berne procedure (intervention treatment)
Both the dissection of the pancreatic body from the portal
vein and the transsection of the pancreas over the portal
vein is not done with the consequence that only one cav-
ity results. Also in this case, multiple stay sutures mark the
dissection margin and support blood sparing surgery.
After subtotal resection of the pancreatic head, reconstruc-
tion is performed in analogy to the original Beger-tech-
nique with a Roux-en-Y jejunal loop and side-to-side
pancreatico-jejunostomy.
Independently of the type of resection (Beger or Berne
procedure), in case of stenosis of the intrapancreatic seg-
ment of the common bile duct which cannot be decom-
pressed by resecting the circumferential fibrous tissue or
in case of accidental opening of the common bile duct
during resection, an additional bilio-digestive anastomo-
sis will be performed.
Primary and secondary endpoints
Primary endpoints
The primary endpoint is combined out of four compo-
nents. In order to adjust for multiple testing a hierarchical
model is used.
1. Duration of surgical procedure [min]
2. Quality of life (EORTC QLQ-C30 questionnaire and the
disease specific module for pancreatic diseases EORTC
QLQ-PAN26) at 12 months after the intervention
3. Duration of stay on the intensive care unit
Flow chartigure 3
Flow chart. If the null hypothesis of no difference can be 
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Secondary endpoints
Frequencies of early and late onset complications such as
intra- or postoperative bleeding with subsequent need for
blood transfusion, pancreatic fistula, postoperative pul-
monary complications, wound infections and re-laparot-
omy; exocrine and endocrine pancreatic function as
determined by levels of HbA1c and stool elastase.
Adverse events and serious adverse events
The term adverse event (AE) covers any sign, symptom,
syndrome, or illness that appears or worsens in a patient
during the period of observation in the clinical trial and
that may impair the well-being of the patient. The term
also covers laboratory findings or results of other diagnos-
tic procedures that are considered to be clinically relevant.
A serious adverse event (SAE) is any adverse event that
occurs at any time during the period of observation that
results in death, is immediately life-threatening, requires
or prolongs hospitalization, or results in persistent or sig-
nificant disability or incapacity.
AEs will be reported to the principle investigator in regular
intervals throughout the study.
SAEs which are meet one of definitions of the secondary
endpoints are treated as SAEs regarding to documenta-
tion, but have not to be reported to the sponsor/principle
investigator within 24 h.
Analysis
A flow chart according to the CONSORT statement is
included [21]. The baseline characteristics of patients in
both groups will be given in a table.
Comparisons will be made of the primary endpoints of
both intervention groups for all patients included in the
study on an intention to treat basis. Furthermore per pro-
tocol analysis will be performed as well as including only
patients strictly treated according to the study protocol.
The outcome measures of the primary endpoint will be
tested for significance with the Mann-Whitney Test (The
test of H0,1 no difference of duration of the surgical procedure
on the level of 5%). If the null hypothesis of no difference
can be rejected the other components can be tested in a
hierarchical way as follows (Fig 3):
1. The test of H0,2 Quality of life in both groups is not equiva-
lent is an equivalence test. Based on preliminary experi-
ences with the EORTC QLQ-C30/PAN26 questionnaires
in pancreatic cancer patients [20], we estimated baseline
raw score values in the range of about 60 (SD 25) before
therapy. When transformed into a percentage scale (with
100% indicating perfect health) this represents values of
45% (SD 18%). After surgery, quality of life can be esti-
mated to improve up to value of 75% (SD 18%). We
assume equivalence for the two resection techniques, if
the two-sided 95% confidence intervals for difference in
quality of life fall within the interval of +/-15%. The value
of 15 as delta was chosen, because the overall effect of sur-
gery is in the range of about 30 percentage points. There-
fore, the minimal clinically relevant difference can be
estimated by halving this effect of surgery. To show equiv-
alence for a delta of 15 (SD 18) with alpha = 5% and beta
= 20%, a sample size of 60 patients is required [22].
2. The test of H0,3 Length of stay on the intensive care unit of
both groups is not equivalent is an equivalent test on the
level of 5%. The zero-hypothesis is declined if the 90%
confidence interval for the difference of mean values of
ICU stay in hours for both groups is in between [-12/12
hours].
3. The test of H0,4 Hospital stay on both groups is not equiva-
lent is an equivalent test on the level of 5%. The null-
hypothesis is declined if the 90% confidence interval for
the difference of mean hospital stay in days for both
groups is in between [-2/2 days].
Once the null hypothesis cannot be rejected no further
testing is applied. All secondary endpoints will be ana-
lyzed using descriptive and graphical methods.
Safety-related data will be analyzed with respect to fre-
quency of:




• Pulmonary infection and wound infection are secondary
endpoints, but are also defined as adverse events. Severe
intraoperative bleeding with need for blood transfusion
will even always be considered a serious adverse event.
Safety-related data will be analyzed with respect to fre-
quency of:
• Serious adverse events and adverse events stratified
according to the organ-systems
• Adverse events stratified by severity
• Adverse events stratified by causalityPage 5 of 6
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All patients scheduled for duodenum preserving pancre-
atic head resection at the Department of Surgery, Univer-
sity of Heidelberg, will be referred to the Center for
Clinical Studies in Surgery (KSC) [23] and screened by
members of the KSC. Approximately 80 patients per year
undergo a duodenum preserving pancreatic head resec-
tion for chronic pancreatitis at the Department of Surgery,
University of Heidelberg. The estimated time frame to
randomize 65 patients is approximately 18 months.
Data will be recorded in clinical reporting files. Double
data entry will be done by two independent staff members
and all analysis are performed with SPSS (SPSS, Chicago,
IL) after plausibility controls and closure of the database.
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